

POWER OF ATTORNEY TO PROSECUTE APPLICATIONS BEFORE THE USPTO

I hereby revoke all previous powers of attorney given in the application identified in the attached statement under 37 CFR 3.73(b).

I hereby appoint:

☒ Practitioner(s) associated with the Customer Number: 45511

OR

☐ Practitioner(s) named below (if more than ten patent practitioners are to be named, then a customer number must be used):

| Name | Registration Number | Name | Registration Number |
|------|---------------------|------|---------------------|
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

as attorney(s) or agent(s) to represent the undersigned before the United States Patent and Trademark Office (USPTO) in connection with any and all patent applications assigned only to the undersigned according to the USPTO assignment records or assignment documents attached to this form in accordance with 37 CFR 3.73(b).

Please change the correspondence address for the application identified in the attached statement under 37 CFR 3.73(b) to:

☒ The address associated with Customer Number: 45511

OR

| | | | |
|--|-------|-----|--|
| <input type="checkbox"/> Firm or Individual Name | | | |
| Address | | | |
| City | State | Zip | |
| Country | | | |
| Telephone | Email | | |

Assignee Name and Address:

Janssen Pharmaceutica N.V.
Turnhoutseweg 30
Beerse, Belgium B-2340

A copy of this form, together with a statement under 37 CFR 3.73(b) (Form PTO/SB/80 or equivalent) is required to be filed in each application in which this form is used. The statement under 37 CFR 3.73(b) may be completed by one of the practitioners appointed in this form if the appointed practitioner is authorized to act on behalf of the assignee, and must identify the application in which this Power of Attorney is to be filed.

SIGNATURE of Assignee of Record

The individual whose signature and title is supplied below is authorized to act on behalf of the assignee

| | | | |
|-----------|--------------------------|-----------|--------------|
| Signature | <i>Mary A. Appollina</i> | Date | 5-13-05 |
| Name | Mary A. Appollina | Telephone | 732-524-3742 |
| Title | Proxy Holder | | |

This collection of information is required by 37 CFR 1.31, 1.32 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 422 and 37 CFR 1.11 and 1.12. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Jose Ignacio Andres-Gil, et al. Confirmation No.: **4854**
Application No.: **10/524,123** Group Art Unit: **1624**
Filing Date: **February 10, 2005** Examiner: **Erich A. Leeser**
For: **Fused Heterocyclic Isoxazoline Derivatives and Their Use as Anti-Depressants**

STATEMENT UNDER 37 CFR § 3.73(b)

JANSSEN PHARMACEUTICA N.V., a CORPORATION, states that it is the assignee of the entire right, title, and interest in the patent application identified above by virtue of a chain of title from the inventors to the assignee as shown below:

From: **INVENTORS ANDRES-GIL, ALCAZAR-VACA, AND FERNANDEZ-GADEA**
TO: **JANSSEN PHARMACEUTICA N.V.** The document was recorded in the Patent and Trademark Office at Reel 016950, Frame 0371.

From: **INVENTORS MEGENS AND BAKKER** To: **JANSSEN PHARMACEUTICA N.V.** The document was recorded in the Patent and Trademark Office at Reel 016950, Frame 0302.

From: **INVENTOR BARTOLOME-NEBRED A** To: **JANSSEN-CILAG S.A.** The document was recorded in the Patent and Trademark Office at Reel 019784, Frame 01706.

From: **JANSSEN-CILAG S.A.** To: **JANSSEN PHARMAECUTICA N.V.** The document was recorded in the Patent and Trademark Office at Reel 016950, Frame 0398.

The undersigned (whose title is supplied below) is empowered to act on behalf of the assignee.

Date: September 7, 2007

/David N. Farsiou/
Name: David N. Farsiou
Attorney for Applicant
Registration No. 44,104

Woodcock Washburn LLP
Cira Centre
2929 Arch Street, 12th Floor
Philadelphia, PA 19104-2891
Telephone: (215) 568-3100
Facsimile: (215) 568-3439

POWER OF ATTORNEY TO PROSECUTE APPLICATIONS BEFORE THE USPTO

I hereby revoke all previous powers of attorney given in the application identified in the attached statement under 37 CFR 3.73(b).

I hereby appoint:

☒ Practitioner(s) associated with the Customer Number: 45511

OR

☐ Practitioner(s) named below (if more than ten patent practitioners are to be named, then a customer number must be used):

| Name | Registration Number | Name | Registration Number |
|------|---------------------|------|---------------------|
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

as attorney(s) or agent(s) to represent the undersigned before the United States Patent and Trademark Office (USPTO) in connection with any and all patent applications assigned only to the undersigned according to the USPTO assignment records or assignment documents attached to this form in accordance with 37 CFR 3.73(b).

Please change the correspondence address for the application identified in the attached statement under 37 CFR 3.73(b) to:

☒ The address associated with Customer Number: 45511

OR

| | | | |
|--|-------|-----|--|
| <input type="checkbox"/> Firm or Individual Name | | | |
| Address | | | |
| City | State | Zip | |
| Country | | | |
| Telephone | Email | | |

Assignee Name and Address:

Janssen Pharmaceutica N.V.
Turnhoutseweg 30
Beerse, Belgium B-2340

A copy of this form, together with a statement under 37 CFR 3.73(b) (Form PTO/SB/80 or equivalent) is required to be filed in each application in which this form is used. The statement under 37 CFR 3.73(b) may be completed by one of the practitioners appointed in this form if the appointed practitioner is authorized to act on behalf of the assignee, and must identify the application in which this Power of Attorney is to be filed.

SIGNATURE of Assignee of Record

The individual whose signature and title is supplied below is authorized to act on behalf of the assignee

| | | | |
|-----------|--------------------------|-----------|--------------|
| Signature | <i>Mary A. Appollina</i> | Date | 5-13-05 |
| Name | Mary A. Appollina | Telephone | 732-524-3742 |
| Title | Proxy Holder | | |

This collection of information is required by 37 CFR 1.31, 1.32 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 422 and 37 CFR 1.11 and 1.12. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Jose Ignacio Andres-Gil, et al. Confirmation No.: **4854**
Application No.: **10/524,123** Group Art Unit: **1624**
Filing Date: **February 10, 2005** Examiner: **Erich A. Leeser**
For: **Fused Heterocyclic Isoxazoline Derivatives and Their Use as Anti-Depressants**

STATEMENT UNDER 37 CFR § 3.73(b)

JANSSEN PHARMACEUTICA N.V., a CORPORATION, states that it is the assignee of the entire right, title, and interest in the patent application identified above by virtue of a chain of title from the inventors to the assignee as shown below:

From: **INVENTORS ANDRES-GIL, ALCAZAR-VACA, AND FERNANDEZ-GADEA**
TO: **JANSSEN PHARMACEUTICA N.V.** The document was recorded in the Patent and Trademark Office at Reel 016950, Frame 0371.

From: **INVENTORS MEGENS AND BAKKER** To: **JANSSEN PHARMACEUTICA N.V.** The document was recorded in the Patent and Trademark Office at Reel 016950, Frame 0302.

From: **INVENTOR BARTOLOME-NEBRED A** To: **JANSSEN-CILAG S.A.** The document was recorded in the Patent and Trademark Office at Reel 019784, Frame 01706.

From: **JANSSEN-CILAG S.A.** To: **JANSSEN PHARMAECUTICA N.V.** The document was recorded in the Patent and Trademark Office at Reel 016950, Frame 0398.

The undersigned (whose title is supplied below) is empowered to act on behalf of the assignee.

Date: September 7, 2007

/David N. Farsiou/
Name: David N. Farsiou
Attorney for Applicant
Registration No. 44,104

Woodcock Washburn LLP
Cira Centre
2929 Arch Street, 12th Floor
Philadelphia, PA 19104-2891
Telephone: (215) 568-3100
Facsimile: (215) 568-3439